"We additionally show using preclinical mouse as well as patient data that treatment with the inhibitor sunitinib significantly reduces the expression of INSR-A. CONCLUSIONS: The current study underscores the oncogenic impact of INSR and suggests that targeting the INSR-A isoform should be considered in therapeutic settings."xsd:string